The FDA issued a warning letter after an inspection of the China plant where Zhuhai United Laboratories makes sterile drugs.

Biotech Rubius Therapeutics will invest large chunk of its recently raised $220 million to build a manufacturing facility.

Zhejiang Huahai Pharmaceutical informed the EMA that it had identified a chemical that might lead to cancer in its valsartan provided to the European market.

Novartis has recalled 11 drugs from the U.S. because their packaging is not child proof. A child broke into the blister pack of an antipsychotic drug.

Fermion Oy has completed an expansion project that will increase capacity at its Hanko plant by 50%.

The FDA has issued a warning letter for a Sichuan Friendly Pharmaceutical plant at Neijiang, Sichuan.

Foshan Jinxiong Technology has been on an import alert list since February, banning all of its products from entering the U.S.

The North American expansions come amid a restructuring at Evonik, which aims to save €200 million in cost by the end of 2020.